DEVELOPING TRUSTWORTHY ARTIFICIAL INTELLIGENCE (AI)-DRIVEN TOOLS TO PREDICT VASCULAR DISEASE RISK AND PROGRESSION
Akronym
VASCUL-AID
Bidragets beskrivning
The aim of VASCUL-AID is to predict the risk of cardiovascular events and progression of the vascular diseases Abdominal Aortic Aneurysm (AAA) and Peripheral Arterial Disease (PAD) to influence the course of disease improving the patient’s quality of life and care and assisting clinicians to make better-informed decisions involving the patient. VASCUL-AID will allow us for the first time to identify patients who are at high risk for AAA growth or PAD progression and cardiovascular events. To this end, we will deliver a clinically relevant and cost-effective trustworthy AI-driven platform (VASCUL-AID) that integrates multi-source parameters including imaging, proteomic and genomic data as well as life-style patient data from wearables to enable personalised vascular disease management. To maximise the personalised prevention strategies, VASCUL-AID leverages visualisation tools to improve clinician-patient communication and empower the patient. The VASCUL-AID platform consists of AI risk-prediction tools, a patient communication app an a clinical dashboard to support clinical decision-making. A particular emphasis is placed on ethics, to ensure beneficial implementation of AI prediction tools.
In this project, we aim to (1) build an EU-wide data infrastructure, (2) develop an AI-based progression prediction tools for AAA and PAD, (3) develop criteria according to the COMET initiative to assess the effectiveness of VASCUL-AID, and (4) clinically test and show proof-of-concept for the VASCUL-AID platform. Once validated, this platform can be extended to other cardiovascular diseases (CVDs) as well. VASCUL-AID brings together 14 leading organisations (and 2 affiliated entities) consisting of clinical academic centres, institutes, universities and SMEs as well as large industry, patients organisations and policy makers that cover the full value chain to enable integration of the platform into clinical practice.
Visa merStartår
2023
Slutår
2029
Beviljade finansiering
BRIGHTFISH BE (BE)
530 000 €
Participant
MEDIZINISCHE HOCHSCHULE BRANDENBURG CAMPUS GMBH (DE)
449 166.25 €
Participant
STICHTING ALLAI NEDERLAND (NL)
250 000 €
Participant
ASKLEPIOS KLINIKEN HAMBURG GMBH (DE)
Participant
STICHTING VUMC (NL)
1 931 131.25 €
Coordinator
Institute of Nuclear Sciences Vinca (RS)
301 730 €
Participant
Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL)
757 996.25 €
Participant
CENTRO HOSPITALAR DE SAO JOAO EPE (PT)
70 000 €
Third party
UNIVERSIDADE DE AVEIRO (PT)
121 830 €
Third party
FACULTY OF MEDICINE, UNIVERSITY OF BELGRADE (RS)
400 000 €
Participant
UNIVERSIDADE DO PORTO (PT)
188 171.25 €
Participant
UNIVERSITEIT TWENTE (NL)
402 500 €
Participant
CENTRE HOSPITALIER UNIVERSITAIRE DE NICE (FR)
435 000 €
Participant
UNIVERSITETET I BERGEN (NO)
439 346.25 €
Participant
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UK)
Participant
Beviljat belopp
5 969 125 €
Finansiär
Europeiska unionen
Typ av finansiering
HORIZON Research and Innovation Actions
Ramprogram
Horizon Europe (HORIZON)
Utlysning
Programdel
Health (11673 Health throughout the Life Course (11689 )
Tema
Trustworthy artificial intelligence (AI) tools to predict the risk of chronic non-communicable diseases and/or their progression (HORIZON-HLTH-2022-STAYHLTH-01-04-two-stageUtlysnings ID
HORIZON-HLTH-2022-STAYHLTH-01-two-stage Övriga uppgifter
Finansieringsbeslutets nummer
101080947
Identifierade teman
cardiovascular diseases